~~<i id='831563A06D'><strike id='831563A06D'><tt id='831563A06D'><pre id='831563A06D'></pre></tt></strike></i>~~

Home» knowledge» knowledge

knowledge

author：fashion 2025-09-29 23:25:54 Page View：16181

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biotech stock slump in 2023: awaiting the turnaround
Next article： New air purifier tech could be key to improving indoor air quality

explore

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Even great ERs can’t make up for American health disparities

PhotobyScottOlson/GettyImagesFrom“Legacy”byUchéBlackstock,M.D.,publishedbyViking,animprintofPenguinP

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Experts study whether long Covid risk adds up with each reinfection

AstudyfromZiyadAl-Aly,clinicalepidemiologistatWashingtonUniversityinSt.Louis,showedthatvaccinationap